Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00464269 · ClinicalTrials.gov registry record · Phase 3
Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00464269 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 400 participants.
The verdict
NCT00464269, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.
Interventions
- OTHER Placebo
- DRUG Brivaracetam 2.5 mg
- DRUG Brivaracetam 10 mg
- DRUG Brivaracetam 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00464269
The ClinicalTrials.gov registry entry for NCT00464269 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00464269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00464269 about?
NCT00464269 is a clinical study titled "Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures". This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.
What is the current status of trial NCT00464269?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2007-09. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00464269?
The interventions under investigation include: Placebo (OTHER), Brivaracetam 2.5 mg (DRUG), Brivaracetam 10 mg (DRUG), Brivaracetam 25 mg (DRUG).
Who is sponsoring clinical trial NCT00464269?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.